Clinical Trial Update: Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 trial evaluating CJ-12420 for erosive esophagitis and gastroesophageal reflux disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erosive Esophagitis
• Gastroesophageal Reflux Disease

Drugs mentioned

• CJ-12420

Snippet

Sponsor: HK inno.N Corporation | Conditions: Erosive Esophagitis, GERD | Phase 2 | Status: COMPLETED